Found: 125
Select item for more details and to access through your institution.
The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis.
- Published in:
- Schizophrenia Bulletin, 2018, v. 44, n. 3, p. 631, doi. 10.1093/schbul/sbx088
- By:
- Publication type:
- Article
Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 6, p. 5481, doi. 10.3390/ijms24065481
- By:
- Publication type:
- Article
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 6, p. 5460, doi. 10.3390/ijms24065460
- By:
- Publication type:
- Article
The impact of affective symptoms on personal recovery of patients with severe mental illness.
- Published in:
- International Journal of Social Psychiatry, 2018, v. 64, n. 6, p. 521, doi. 10.1177/0020764018784610
- By:
- Publication type:
- Article
Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 5, p. 1209, doi. 10.1111/bjh.17994
- By:
- Publication type:
- Article
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 61, doi. 10.1111/bjh.17498
- By:
- Publication type:
- Article
Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 307, doi. 10.1111/bjh.16042
- By:
- Publication type:
- Article
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 1, p. e1, doi. 10.1111/bjh.16117
- By:
- Publication type:
- Article
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 184, doi. 10.1111/bjh.15791
- By:
- Publication type:
- Article
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 175, doi. 10.1111/bjh.15784
- By:
- Publication type:
- Article
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 852, doi. 10.1111/bjh.15877
- By:
- Publication type:
- Article
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 606, doi. 10.1111/bjh.15581
- By:
- Publication type:
- Article
Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 4, p. 597, doi. 10.1111/bjh.14398
- By:
- Publication type:
- Article
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 33, doi. 10.1111/bjh.15018
- By:
- Publication type:
- Article
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 2, p. 286, doi. 10.1111/bjh.14660
- By:
- Publication type:
- Article
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 5, p. 760, doi. 10.1111/bjh.14129
- By:
- Publication type:
- Article
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 3, p. 425, doi. 10.1111/bjh.14075
- By:
- Publication type:
- Article
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 3, p. 392, doi. 10.1111/bjh.13834
- By:
- Publication type:
- Article
The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 2, p. 281, doi. 10.1111/bjh.13377
- By:
- Publication type:
- Article
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 1, p. 125, doi. 10.1111/bjh.13269
- By:
- Publication type:
- Article
The bruton tyrosine kinase inhibitor ibrutinib ( PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 2, p. 177, doi. 10.1111/bjh.12867
- By:
- Publication type:
- Article
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.
- Published in:
- Molecular Cancer, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1476-4598-12-50
- By:
- Publication type:
- Article
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1005, doi. 10.1002/ajh.26595
- By:
- Publication type:
- Article
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 914, doi. 10.1002/ajh.26206
- By:
- Publication type:
- Article
The cXcr4-sTaT3-il-10 Pathway controls the immunoregulatory Function of chronic lymphocytic leukemia and is Modulated by lenalidomide.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2017.01773
- By:
- Publication type:
- Article
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0083830
- By:
- Publication type:
- Article
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
- Published in:
- Oncogene, 2005, v. 24, n. 27, p. 4462, doi. 10.1038/sj.onc.1208621
- By:
- Publication type:
- Article
KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway.
- Published in:
- Oncogene, 2005, v. 24, n. 12, p. 2067, doi. 10.1038/sj.onc.1208442
- By:
- Publication type:
- Article
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
- Published in:
- Oncogene, 2003, v. 22, n. 50, p. 8093, doi. 10.1038/sj.onc.1207097
- By:
- Publication type:
- Article
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 507, doi. 10.3390/cancers15020507
- By:
- Publication type:
- Article
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 15, p. 6559, doi. 10.1002/cam4.2545
- By:
- Publication type:
- Article
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
- Published in:
- Nature Cell Biology, 2012, v. 14, n. 3, p. 276, doi. 10.1038/ncb2432
- By:
- Publication type:
- Article
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
- Published in:
- 2014
- By:
- Publication type:
- journal article
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.689472
- By:
- Publication type:
- Article
Restoring Quality of Life and Hematologic Function with Ibrutinib in Treatment-Naive Patients with Chronic Lymphocytic Leukemia in the RESONATE-2 Study.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2016, v. 7, n. 9, p. 58
- By:
- Publication type:
- Article
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
- Published in:
- Nature Communications, 2016, v. 7, n. 5, p. 11589, doi. 10.1038/ncomms11589
- By:
- Publication type:
- Article
CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S322, doi. 10.1016/S2152-2650(21)01759-6
- By:
- Publication type:
- Article
CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S316, doi. 10.1016/S2152-2650(21)01747-X
- By:
- Publication type:
- Article
Poster: CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S222, doi. 10.1016/S2152-2650(21)01401-4
- By:
- Publication type:
- Article
Poster: CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01393-8
- By:
- Publication type:
- Article
P300 Induces STAT3 Acetylation and Provides CLL Cells with Survival Advantage.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S277, doi. 10.1016/j.clml.2019.07.210
- By:
- Publication type:
- Article
Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S274, doi. 10.1016/j.clml.2019.07.205
- By:
- Publication type:
- Article
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S13, doi. 10.1016/j.clml.2017.09.041
- By:
- Publication type:
- Article